ABSTRACT
PURPOSE: To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC). PATIENTS AND METHODS: In this single-arm phase II trial, oral continuous sorafenib was administered in 28-day cycles. Patients had Subject(s)
Antineoplastic Agents/therapeutic use
, Benzenesulfonates/therapeutic use
, Carcinoma, Squamous Cell/drug therapy
, Head and Neck Neoplasms/drug therapy
, Nasopharyngeal Neoplasms/drug therapy
, Pyridines/therapeutic use
, Adult
, Aged
, Carcinoma, Squamous Cell/mortality
, Carcinoma, Squamous Cell/secondary
, Disease Progression
, Disease-Free Survival
, Female
, Head and Neck Neoplasms/mortality
, Head and Neck Neoplasms/pathology
, Humans
, Male
, Middle Aged
, Nasopharyngeal Neoplasms/mortality
, Nasopharyngeal Neoplasms/pathology
, Neoplasm Recurrence, Local
, Niacinamide/analogs & derivatives
, Phenylurea Compounds
, Protein Kinase Inhibitors/therapeutic use
, Sorafenib
, Survival Rate
, raf Kinases/antagonists & inhibitors
